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Summary
Background Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in 
the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention 
Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared 
anastrozole with placebo, with the objective of determining the efficacy of anastrozole for preventing breast cancer 
(both invasive and ductal carcinoma in situ) in the post-treatment period.
Methods IBIS-II is an international, randomised, double-blind, placebo-controlled trial. Postmenopausal women at 
increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole 
(1 mg per day, oral) or matching placebo daily for 5 years. After treatment completion, women were followed on a 
yearly basis to collect data on breast cancer incidence, death, other cancers, and major adverse events (cardiovascular 
events and fractures). The primary outcome was all breast cancer.
Findings 3864 women were recruited between Feb 2, 2003, and Jan 31, 2012. 1920 women were randomly assigned to 
5 years anastrozole and 1944 to placebo. After a median follow-up of 131 months (IQR 105–156), a 49% reduction in 
breast cancer was observed for anastrozole (85 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). 
The reduction was larger in the first 5 years (35 vs 89, 0·39, 0·27–0·58, p<0·0001), but still significant after 5 years 
(50 vs 76 new cases, 0·64, 0·45–0·91, p=0·014), and not significantly different from the first 5 years (p=0·087). 
Invasive oestrogen receptor-positive breast cancer was reduced by 54% (HR 0·46, 95% CI 0·33–0·65, p<0·0001), with 
a continued significant effect in the period after treatment. A 59% reduction in ductal carcinoma in situ was observed 
(0·41, 0·22–0·79, p=0·0081), especially in participants known to be oestrogen receptor-positive (0·22, 0·78–0·65, 
p<0·0001). No significant difference in deaths was observed overall (69 vs 70, HR 0·96, 95% CI 0·69–1·34, p=0·82) or 
for breast cancer (two anastrozole vs three placebo). A significant decrease in non-breast cancers was observed for 
anastrozole (147 vs 200, odds ratio 0·72, 95% CI 0·57–0·91, p=0·0042), owing primarily to non-melanoma skin 
cancer. No excess of fractures or cardiovascular disease was observed.
Interpretation This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the 
post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the 
effect on breast cancer mortality.
Funding Cancer Research UK, the National Health and Medical Research Council Australia, Breast Cancer Research 
Foundation, Sanofi Aventis, and AstraZeneca.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Early work on therapeutic prevention of breast cancer 
has focused on selective oestrogen receptor modulators 
(SERMs), such as tamoxifen and raloxifene, which 
show anti-oestrogenic effects on the breast, as well as 
agonistic or antagonistic effects on some other organs. 
In a meta-analysis of several SERMs,1 a 38% reduction 
in all breast cancer was observed, driven by 50% 
reduction of oestrogen receptor-positive tumours, but 
no effect on oestrogen receptor-negative tumours. 
Long-term follow up of two of these trials has shown 
that the effects of tamoxifen continue with a constant 
29% annual preventive effect for at least 15 years after 
completion of treatment.2,3
A greater short-term reduction in breast cancer 
incidence was seen in two trials using, the aromatase 
inhibitors, anastrozole4 and exemestane.5 The MAP.3 trial5 
compared exemestane with placebo in postmenopausal 
women at high risk of developing breast cancer and found 
a significant reduction in the incidence of all breast cancer 
by 53% and a 65% reduction in invasive breast cancer 
after a median follow-up of 35 months. However, all 
women were unblinded after the initial publication, so it 
was not possible to study a post-treatment effect, as has 
been seen with tamoxifen.2
The International Breast Cancer Intervention Study II 
(IBIS-II) was initiated in 2003 and recruited post-
menopausal women without breast cancer but at high 
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risk of developing it to receive either anastrozole (1 mg 
daily) or matching placebo. The first analysis after a 
median follow-up of 60 months (IQR 36–85) reported a 
significant reduction in incidence of 53% for all breast 
cancer (including ductal carcinoma in situ).4 A 58% 
reduction in incidence of invasive oestrogen receptor-
positive breast cancer and a 70% reduction in incidence 
of ductal carcinoma in situ was observed for anastrozole. 
As reported in adjuvant trials,6,7 the main adverse events 
with anastrozole were fractures, joint-related effects, 
and menopausal symptoms, which are associated with 
an almost complete elimination of oestrogen in post-
menopausal women using aromatase inhibitors.
A long-term term reduction of breast cancer incidence 
for anastrozole or any aromatase inhibitor has not been 
established, as it has for tamoxifen.2,3 Such a result is likely 
to substantially improve the benefit-risk ratio, as side-
effects are uncommon after treatment cessation. The 
objective of this study was to determine the long-term 
efficacy of anastrozole for preventing breast cancer (both 
invasive and ductal carcinoma in situ) in the post-
treatment period.
Methods
Study design and participants
IBIS-II is an international, randomised, double-blind, 
placebo-controlled trial. Detailed study design and 
inclusion and exclusion criteria have previously been 
reported.4 In brief, high-risk postmenopausal women 
aged 40–70 years were recruited between Feb 2, 2003, and 
Jan 31, 2012, in 153 breast cancer treatment centres across 
18 countries (appendix p 3). Specific risk criteria for entry 
were broad and have previously been reported.4 They 
were designed to include women aged 45–60 years who 
had a relative risk of breast cancer that was at least twice 
as high as that in the general population, those aged 
60–70 years who had a risk that was at least 1·5 times 
higher, and those aged 40–44 years who had a risk that 
was at least four times higher. The exclusion criteria were 
being premenopausal, previous breast cancer including 
ductal carcinoma in situ diagnosed more than 6 months 
before trial entry, current or previous tamoxifen, 
raloxifene, or other SERM use for more than 6 months, 
or participation in IBIS-I, unless off-trial therapy for at 
least 5 years, intention to continue using oestrogen-based 
hormone replacement therapy, or previous or planned 
prophylactic mastectomy.
The trial was approved by the UK North West 
Multi-Centre Research Ethics Committee and was 
done in accordance with the Declaration of Helsinki 
(1996 revision), under the principles of good clinical 
practice. All participants provided written, informed 
consent to join the study, provide baseline and follow-up 
blood samples, and have their past and future health 
records examined, including access to mammograms 
and pathology material.
Randomisation and masking
Consenting eligible women were randomly assigned (1:1) 
to either anastrozole (1 mg per day, oral) or matching 
placebo daily for 5 years. Randomisation was stratified by 
country. All participants and medical personnel were 
blinded to treatment allocation, which was only held by 
the central study statistician. Unblinding was only 
permitted if the participant developed breast cancer, 
when a clinician considered there to be valid medical or 
Research in context
Evidence before this study
At the time of the initial publication of this trial, we searched 
PubMed for reports published in English between Jan 1, 1980, 
and May 30, 2013. We used the search terms “breast cancer”, 
“prevention”, and “aromatase inhibitor”. Only one other 
prevention trial using an aromatase inhibitor had been reported 
and it has been discussed. However, we identified several 
adjuvant trials using aromatase inhibitors in which contralateral 
tumours were reported. We also identified an overview of 
selective oestrogen receptor modulators for breast cancer 
prevention. Two large trials in which aromatase inhibitors are 
being assessed for prevention of ductal carcinoma were also 
identified. For this Article, we repeated the search up to 
Oct 30, 2019. A US Preventive Services Task Force review was 
found, but no new studies on breast cancer prevention with 
aromatase inhibitors were identified.
Added value of this study
We report results of the randomised IBIS-II trial on the 
extended duration of benefit of anastrozole in preventing 
breast cancer up to 12 years after entry and indicate for the first 
time a long-term benefit, which is larger than that seen for 
tamoxifen in this period. No excess of fractures, other cancers, 
cardiovascular disease, or death from any specific cause was 
seen in the extended follow-up. The number needed to treat to 
prevent one breast cancer has been reduced to 29.
Implications of all the available evidence
Our results provide additional support for the use of 
anastrozole as the treatment of choice for breast cancer risk 
reduction in most postmenopausal women at high risk of 
developing breast cancer. Its use has been supported by the 
National Institute for Health and Care Excellence in the UK and 
the US Preventive Services Task Force. Identification of women 
at high risk of early symptoms of oestrogen depletion and their 
management remains a challenge.
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safety reasons, or the participant requested unblinding. 
Treatment allocation still remains largely blinded for 
investigators and participating women who have not 
developed breast or any other cancer (81·3% anastrozole 
vs 76·7% placebo, p=0·0053). A further analysis was 
planned to take place around 5 years after the last report,4 
and this analysis is provided 6 years after that report. 
The decision to analyse the data was made without 
looking at the results beforehand.
Procedures
After treatment completion, women were followed on a 
yearly basis to collect data on breast cancer incidence, 
death, other cancers, and major adverse events (cardio-
vascular events, fractures). In the UK, these events were 
also collected through cancer registries and National 
Health Services (NHS Digital). In non-UK centres, 
annual questionnaire or annual clinic visits were used to 
collect these data.
Outcomes
The primary outcome was the development of histol-
ogically confirmed breast cancer—either invasive or 
non-invasive (ductal carcinoma in situ). Secondary 
outcomes were oestrogen receptor-positive breast cancer, 
breast cancer mortality, other cancers, cardiovascular 
disease, fractures, and all-cause mortality. Exploratory 
analyses reported treatment effects by more detailed 
breast cancer type, specific baseline patient charac-
teristics (age, body-mass index [BMI], previous use of 
hormone replacement therapy, and previous lobular 
carcinoma in situ or atypical hyperplasia), and other 
major cancers by site.
Statistical analysis
All analyses were done on an intention-to-treat basis, 
including all randomly assigned patients. Analyses of 
the efficacy endpoints were based on hazard ratios 
(HRs) using Cox proportional hazard models,8,9 with 
corresponding 95% CIs, and survival curves were 
estimated using the Kaplan-Meier method.10 Only major 
adverse effects (other cancers, cardiovascular events, 
fractures, and deaths) were routinely collected after 
5 years in all patients. Side-effects and secondary 
outcomes were compared between treatment groups 
using odds ratios (ORs) and Fisher exact significance 
tests. All p values were two-sided. All analyses were done 
using STATA version 15.1. This trial is registered as an 
International Standard Randomised Controlled Trial, 
number ISRCTN31488319.
Role of the unding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of the report. The corresponding author had full access 
to all the data in the study and had final responsibility 
for the decision to submit for publication.
Results
All women randomly assigned to treatment (N=3864, 
1920 anastrozole and 1944 placebo) have been included in 
this analysis. 3704 (95·9%) were still at risk of devel-
oping breast cancer after the 5-year treatment period 
(1866 anastrozole, 1838 placebo) and follow-up is ongoing 
(appendix p 3). Median follow-up for this analysis was 
131 months (IQR 106–156), and 41 295 women-years of 
follow-up have been accrued (anastrozole 20 803, placebo 
20 491), of which 22 367 women-years were accrued after 
5 years of follow-up (anastrozole 11 339, placebo 11 028). 
Median age at study entry was 59·4 years (IQR 55·0–63·4), 
1893 women (47·0%) had used hormone replacement 
therapy before entering the trial, and 2631 (68·1%) had a 
BMI of more than 25kg/m². Other baseline demographics 
are shown in the appendix (p 1).
250 breast cancers have been reported (85 anastrozole 
[4·4%] vs 165 placebo [8·5%]; table 1), with a highly 
significant 49% reduction for all breast cancer with 
Number of events, 
anastrozole vs 
placebo
Hazard ratio 
(95% CI)
p value pheterogeneity*
Overall 85 vs 165 0·51 (0·39–0·66) <0·0001 ··
0–5 years 35 vs 89 0·39 (0·27–0·58) <0·0001 0·087
>5 years 50 vs 76 0·64 (0·45–0·91) 0·014 ··
Invasive oestrogen receptor-positive 48 vs 103 0·46 (0·33–0·65) <0·0001 ··
0–5 years 20 vs 51 0·39 (0·23–0·66) <0·0001 0·43
>5 years 28 vs 52 0·52 (0·33–0·83) 0·0062 ··
All ductal carcinoma in situ 13 vs 31 0·41 (0·22–0·79) 0·0081 ··
0–5 years 5 vs 17 0·29 (0·11–0·80) 0·016 0·43
>5 years 8 vs 14 0·56 (0·23–1·32) 0·18 ··
*0–5 years vs >5 years.
Table 1: Number of breast cancer events and hazard ratios
Figure 1: Cumulative incidence for all breast cancer by treatment allocation and follow-up period
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anastrozole (HR 0·51, 95% CI 0·39–0·66, p<0·0001). 
The reduction in incidence in the first 5 years of follow-
up was 61% (0·39, 0·27–0·58, p<0·0001), and a smaller 
but still significant 37% reduction (0·64, 0·45–0·91, 
p=0·014) was seen in subsequent years, which was still 
larger than that seen for tamoxifen in previous trials. 
The effects in the two periods were not significantly 
different (p=0·087) and a Hosmer-Lemeshow test for 
non-pro portional hazards was not significant (p=0·073). 
After 12 years of follow-up, the estimated risk of 
developing breast cancer was 8·8% (IQR 7·6–10·3) in 
the placebo group compared with 5·3% (4·3–6·6) in the 
anastrozole group (figure 1), and the number needed to 
treat for 5 years to prevent one breast cancer was 29.
Overall 203 (81·2%) of the breast cancers were invasive, 
and 151 (74·4%) of these were reported as oestrogen 
receptor-positive. A 54% reduction in incidence with 
anastrozole was observed for oestrogen receptor-positive 
cancers (HR 0·46, 95% CI 0·33–0·65, p<0·0001), with a 
larger 61% reduction in the first 5 years (0·39, 0·23–0·66, 
p<0·0001; figure 2), followed by a 48% reduction (0·52, 
0·33–0·83, p=0·0062). A small, non-significant reduction 
in incidence was observed for invasive oestrogen receptor-
negative breast cancer in the anastrozole group (0·77, 
0·41–1·44, p=0·41; figure 2). A significant reduction 
in incidence for anastrozole was also found for ductal 
carcinoma in situ (0·41, 0·22–0·79, p=0·0081), in 
particular for lesions known to be oestrogen-positive 
(0·22, 0·07–0·65, p=0·0062; figure 2).
No clear heterogeneity or trend was observed for 
differences in the preventive effect of anastrozole by 
other tumour characteristics (appendix p 2). Anastrozole 
reduced incidence of invasive HER2-negative cancers by 
43% (HR 0·57, 95% CI 0·41–0·78), which was similar to 
that for invasive HER2-positive cancers (0·52, 0·23–1·17; 
appendix p 2).
Exploratory analyses of baseline characteristics did not 
show any significant heterogeneity by age, BMI, previous 
hormone replacement therapy use, or previous lobular 
carcinoma in situ or atypical hyperplasia (appendix p 2). 
Reductions in incidence did not differ between treatment 
groups for women with a BMI of more than 30 kg/m² 
and or who took hormone replacement therapy before 
trial entry.
Overall, a 28% reduction in cancer incidence at non-
breast sites occurred (147 vs 200 cases, OR 0·72, 95% CI 
0·57–0·91, p=0·0042; table 2). Secondary analyses 
showed that this reduction was driven largely by a 
reduction in the incidence of non-melanoma skin cancer 
(43 vs 73 cases, 0·59, 0·39–0·87, p=0·0058), and no effect 
on other specific cancers was apparent (table 2). In 
particular, no reduction in the incidence of endometrial 
cancer occurred due to oestrogen deprivation from 
anastrozole, although oestrogen is thought to be a major 
driver of this cancer.11 Additionally, the early reduction 
seen for colorectal cancers4 has not been extended with 
longer follow-up.
No effect was seen on any other major adverse event 
(table 3). In particular, there was no excess of fractures 
overall (380 vs 373, OR 1·04, 95% CI 0·88–1·22). A small 
non-significant increase in number of events during the 
active treatment period (198 vs 186, 1·09, 0·87–1·35) was 
counterbalanced by slight reduction of events after 
treatment was completed (182 vs 187, 0·98, 0·79–1·23). 
Myocardial infarctions were evenly distributed between 
Anastrozole 
N=1920, n (%)
Placebo, 
N=1944, n (%)
Odds ratio 
(95% CI)
Total 147 (7·1%) 200 (9·8%) 0·72 (0·57–0·91)
Skin 52 (2·7%) 85 (4·4%) 0·61 (0·42–0·88)
Non-melanoma 43 (2·2%) 73 (3·8%) 0·59 (0·39–0·87)
Melanoma 9 (0·5%) 12 (0·6%) 0·76 (0·28–1·97)
Gynaecological 14 (0·7%) 20 (1·0%) 0·71 (0·33–1·47)
Endometrial 5 (0·3%) 7 (0·4%) 0·72 (0·18–2·65)
Ovarian 7 (0·4%) 10 (0·5%) 0·71 (0·23–2·06)
Respiratory 13 (0·7%) 13 (0·7%) 1·01 (0·43–2·38)
Lung 11 (0·6%) 12 (0·6%) 0·93 (0·37–2·30)
Gastrointestinal 24 (1·3%) 33 (1·7%) 0·81 (0·45–1·43)
Colorectal 11 (0·6%) 16 (0·8%) 0·69 (0·29–1·60)
Table 2: Cancers other than breast
Figure 2: Hazard ratios for subgroup analyses by follow-up period
Grey squares indicate the amount of information available for this comparison, largely based on the number of 
events.
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Number 
of events
Hazard ratio
(95% CI)
Anastrozole, N=1920, 
all years (>5 years)
Placebo, N=1944, 
all years (>5 years)
Odds ratio (95% CI), 
all years
Fractures 380 (182) 373 (186) 1·04 (0·88–1·22)
Myocardial infarction 16 (8) 14 (8) ··
Deep vein thrombosis* 13 (6) 17 (5) ··
Pulmonary embolism 17 (11) 12 (7) ··
Transient ischaemic attack† 24 (14) 20 (9) ··
Stroke 23 (15) 17 (9) ··
*In the absence of pulmonary embolism. †In the absence of stroke. Numbers in parentheses refer to events occurring 
in the post-treatment period (>5 year follow-up).
Table 3: Major adverse events
Articles
www.thelancet.com   Published online December 12, 2019   https://doi.org/10.1016/S0140-6736(19)32955-1 5
treatment groups (table 3), and no differences in number 
of events were observed in the first 5 years (eight vs eight) 
or in follow-up after treatment (eight vs six). Numbers of 
deep vein thromboses were slightly increased in the 
placebo group, with no differences observed in the two 
periods (table 3). Cases of pulmonary embolism were 
non-significantly more frequent with anastrozole but no 
differences were observed during treatment compared 
with after treat ment (table 3). Transient ischaemic attacks 
and strokes were non-significantly more common with 
anastrozole compared with placebo (46 vs 36, p=0·24).
Other less serious side-effects observed in the first 
5 years during treatment with anastrozole,4 including 
arthralgia, joint stiffness, hot flushes, night sweats, 
vulvovaginal dryness, hypertension, and dry eyes, were 
not collected after the 5-year treatment period. However, 
even within the treatment period they were most common 
in the first year of treatment, so it is unlikely that there 
will be material differences in the post-treatment period. 
All participants have now completed treatment and full 
5-year adherence was 74·6% for anastrozole compared 
with 77·0% for placebo (HR 0·89, 95% CI 0·79–1·01, 
p=0·081; appendix p 4), indicating that side-effects of 
anastrozole had little effect on treatment adherence.
139 (3·6%) women died during the study (69 anastrozole 
vs 70 placebo; table 4), with no difference between the 
two treatment groups (HR 0·96, 95% CI 0·69–1·34, 
p=0·82). Overall, no effect of anastrozole was seen 
for breast cancer-specific mortality (three anastrozole vs 
two placebo), but numbers are very small. Given the 
small number of deaths and the relatively young median 
age at entry (59·4 years), substantially longer follow-up 
will be needed to determine whether anastrozole affects 
breast cancer and other cause mortality. Deaths from 
cancers other than breast did not differ between 
treatment groups (p=0·39).
Discussion
This updated analysis of the IBIS-II trial provides 
additional support for the use of anastrozole in breast 
cancer prevention for high-risk postmenopausal women. 
The large 61% reduction in breast cancer incidence in the 
first 5 years has been maintained in subsequent follow-up 
to 12 years. The significant 36% reduction during post-
treatment follow-up was not significantly smaller than 
during treatment, and still greater than that observed 
for tamoxifen, which has produced a roughly constant 
29% reduction for 20 years.2 The number needed to treat 
to prevent one breast cancer during the first 12 years of 
follow-up was 29, which compares favourably with the 
58 needed for tamoxifen at that time.2 Very few deaths 
from breast cancer have occurred to date, but it is too 
early to expect an effect on this outcome, which is a 
limitation of this analysis. The reduction with anastrozole 
was primarily seen in oestrogen receptor-positive cancers, 
which suggests that the effect on mortality will be smaller 
than that for incidence. The effects were greatest for 
oestrogen receptor-positive tumours, but an unexpected 
and non-significant 27% reduction was also seen for 
receptor-negative cancers, which will need further follow-
up to validate.
The previously observed4 reduction of other cancers 
with anastrozole, notably non-melanoma skin cancer, 
has continued with longer follow up. No other side-
effects have been identified with longer follow-up, and 
the small 11% excess of fractures during the active 
treatment period has not continued after 5 years of 
follow-up. A limitation of this analysis is that routine 
collection of less serious side-effects was not done after 
the 5-year treatment period.
All women have completed the active follow-up period 
of the trial and now are followed for long-term outcomes 
by various methods. In the UK, long-term data are 
collected through national registries for deaths, cancers, 
and major predefined adverse events, so we are confident 
that data are complete. Additionally, we still collect data 
through annual questionnaires where appropriate. 
For international centres, annual questionnaires were 
used to collect information on all primary and secondary 
outcomes. However, data on lesser side-effects, such as 
hot flushes and musculoskeletal events, were only 
collected during the 5-year treatment period.
In conclusion, these updated results show a continuing 
long-term effect of 5 years of anastrozole treatment in 
preventing breast cancer in high-risk postmenopausal 
women. No new major adverse events were identified. 
Overall, our data substantially strengthen the findings 
from our initial report after 5 years of follow-up.4 
In the UK, the National Institute for Health and Care 
Excellence has now recommended the use of anastrozole 
for breast cancer prevention in high-risk postmenopausal 
women,12 and in the USA, the US Preventive Services 
Task Force has also supported its use.13 The benefits of 
anastrozole, in terms of the reduction in risk of breast 
cancer in high-risk postmenopausal women, extend 
beyond the 5-year treatment period.
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Anastrozole, 
N=1920, n (%)
Placebo, 
N=1944, n (%)
Hazard ratio 
(95% CI)
All 69 (3·6%) 70 (3·6%) 0·96 (0·69–1·34)
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